<DOC>
	<DOC>NCT00154804</DOC>
	<brief_summary>CCRT with twice weekly paclitaxel and cisplatin in patient with locally advanced esophageal cancer.</brief_summary>
	<brief_title>CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer</brief_title>
	<detailed_description>The purpose of this study is to find out the clinical and pathological response rates of pre-operative concurrent chemoradiotherapy (CCRT) with twice weekly paclitaxel and cisplatin in patient with locally advanced esophageal cancer.</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1. Pathologically proven SCC or adenocarcinoma of esophagus . 2. Locally advanced esophageal cancer , defined as T3 and/or N1 disease.( AJCC 1998) 3. M1a disease defined ( AJCC 1998) , including celiac lymph node for lower thoracic esophageal cancer and cervical lymph node involvement for upper thoracic esophageal cancer . 4. Age ≧ 18 ys 5. KPS ≧ 60% 6. Hemogram : WBC ≧ 4000/mm3 or ANC ≧ 2000 /mm3 and Platelet ≧ 100,000/mm3 . Biochemistry : GOT/GPT ≦ 3.5 times , Cr ≦ 1.5 mg/dl and Bilirubin ≦ 2.0 mg/dl . 1. Invasion to surrounding organ ( T4 disease ) . 2. Distant metastasis , except M1a disease . 3. Patients who refuse operation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>Concurrent Chemoradiotherapy</keyword>
	<keyword>Esophageal Cancer</keyword>
</DOC>